全文获取类型
收费全文 | 8927篇 |
免费 | 611篇 |
国内免费 | 75篇 |
专业分类
耳鼻咽喉 | 46篇 |
儿科学 | 235篇 |
妇产科学 | 261篇 |
基础医学 | 1408篇 |
口腔科学 | 219篇 |
临床医学 | 766篇 |
内科学 | 2089篇 |
皮肤病学 | 213篇 |
神经病学 | 974篇 |
特种医学 | 309篇 |
外科学 | 804篇 |
综合类 | 40篇 |
一般理论 | 5篇 |
预防医学 | 699篇 |
眼科学 | 191篇 |
药学 | 591篇 |
中国医学 | 52篇 |
肿瘤学 | 711篇 |
出版年
2023年 | 94篇 |
2022年 | 86篇 |
2021年 | 302篇 |
2020年 | 226篇 |
2019年 | 272篇 |
2018年 | 317篇 |
2017年 | 239篇 |
2016年 | 282篇 |
2015年 | 323篇 |
2014年 | 416篇 |
2013年 | 472篇 |
2012年 | 775篇 |
2011年 | 789篇 |
2010年 | 402篇 |
2009年 | 396篇 |
2008年 | 564篇 |
2007年 | 619篇 |
2006年 | 557篇 |
2005年 | 566篇 |
2004年 | 486篇 |
2003年 | 399篇 |
2002年 | 356篇 |
2001年 | 50篇 |
2000年 | 47篇 |
1999年 | 63篇 |
1998年 | 58篇 |
1997年 | 48篇 |
1996年 | 40篇 |
1995年 | 55篇 |
1994年 | 32篇 |
1993年 | 49篇 |
1992年 | 20篇 |
1991年 | 21篇 |
1990年 | 23篇 |
1989年 | 12篇 |
1988年 | 17篇 |
1987年 | 14篇 |
1986年 | 13篇 |
1985年 | 13篇 |
1984年 | 9篇 |
1983年 | 9篇 |
1982年 | 10篇 |
1981年 | 8篇 |
1980年 | 7篇 |
1979年 | 11篇 |
1976年 | 5篇 |
1974年 | 6篇 |
1970年 | 3篇 |
1969年 | 4篇 |
1946年 | 3篇 |
排序方式: 共有9613条查询结果,搜索用时 15 毫秒
1.
Koji Sasaki Tapan Kadia Kebede Begna Courtney D. DiNardo Gautam Borthakur Nicholas J. Short Nitin Jain Naval Daver Elias Jabbour Guillermo Garcia-Manero Guillermo Montalban Bravo Lucia Masarova Sherry Pierce Marina Konopleva Farhad Ravandi Ayalew Tefferi Hagop Kantarjian 《American journal of hematology》2022,97(1):68-78
The progress with intensive chemotherapy and supportive care measures has improved survival in patients with newly diagnosed acute myeloid leukemia (AML). Given the recent development of effective low intensity therapies, an optimal decision on the therapy intensity may improve survival through the avoidance of early mortality. We reviewed the outcome of 3728 patients with newly diagnosed AML who received intensive chemotherapy between August 1980 and May 2020. Intensive chemotherapy was defined as a cumulative cytarabine dose ≥ 700 mg/m2 during induction therapy. We divided the whole cohort into a training and validation group at a 3:1 ratio. The population was divided into a training (2790 patients) and a validation cohort (938 patients). The median age was 55 years (range, 15-99). Among them, 442 patients (12%) had core-binding factor AML. Binary logistic regression identified older age, worse performance status, hyperbilirubinemia, elevated creatinine, hyperuricemia, cytogenetic abnormalities other than CBF and -Y, and pneumonia as adverse prognostic factors for an early 4-week mortality. This risk classification for early mortality was verified in the validation cohort of patients. In the validation cohort of more recently treated patients from 2000 to 2017, the 4-week mortality rates with intensive chemotherapy were 2%, 14%, and 50% in the low-, high-, and very high-risk group, respectively. The mortality rates with low intensity therapies were 3%, 9%, and 20%, respectively. The risk classification guides treatment intensity by the assessment of age, frailty, organ dysfunction, cytogenetic abnormality, and infection to avoid early mortality. 相似文献
2.
3.
Marco Maruzzo Umberto Basso Eugenio Borsatti Laura Evangelista Filippo Alongi Orazio Caffo Francesca Maines Sara Galuppo Rocco De Vivo Fable Zustovich Dario Palleschi Andrea Zivi Teodoro Sava Mariella Sorarù Roberto Iacovelli Maurizio Nicodemo Susanne Baier Lucia Fratino Vittorina Zagonel 《Clinical genitourinary cancer》2019,17(1):e187-e194
Background
Radium 223 was introduced for metastatic castration-resistant prostate cancer based on the results of a randomized controlled trial showing risk reduction for death and skeletal events. Our aim was to evaluate the outcome of patients receiving radium 223 in a real-world setting.Patients and Methods
We conducted a multicenter retrospective analysis in the Triveneto region of Italy.Results
One hundred fifty-eight patients received radium 223 in our region. After a median follow-up of 9.5 months, 75 patients died. The median overall survival (OS) was 14.2 months, and the median progression-free survival (PFS) was 6.2 months. Seventy-one (45%) patients achieved progression as best response. Thirty-seven (23%) patients stopped the treatment early because of progression. Eastern Cooperative Oncology Group performance status was prognostic for OS (18.4 vs. 12.3 vs. 7.5 months; 0 vs. 1, P = .0062; 0 vs. 2, P = .0002), whereas previous prostatectomy or docetaxel exposure were not. A neutrophil to lymphocytes ratio ≥ 3 significantly impacted OS (18.1 vs. 9.7 months; P < .001) and slightly impacted PFS (6.6 vs. 5.6 months; P = .05). Patients with a baseline alkaline phosphatase (ALP) value ≥ 220 U/L had worse OS and PFS (24.1 vs. 10.5 months; 7.2 vs. 5.5 months; P < .001). Patients with changes in ALP value achieved better OS (P = .029) and PFS (P = .002). There was no difference according to the line of therapy (0 vs. ≥ 1; P = .490). The main grade 3/4 toxicities were anemia, asthenia, and thrombocytopenia.Conclusion
This large real-world report confirms comparable OS and PFS data when compared with the pivotal study, as well as the predictive role of ALP and neutrophil to lymphocytes ratio. The definition of the optimal position of radium 223 in the treatment of metastatic castration-resistant prostate cancer has still to be defined. 相似文献4.
Oliver Sartor MD Daniel Heinrich MD Neil Mariados MD Maria José Méndez Vidal MD Daniel Keizman MD Camilla Thellenberg Karlsson MD Avivit Peer MD Giuseppe Procopio MD Stephen J. Frank MD Kalevi Pulkkanen MD Eli Rosenbaum MD Stefano Severi MD José Trigo MD Lucia Trandafir MD Volker Wagner MD Rui Li MS Luke T. Nordquist MD 《The Prostate》2019,79(14):1683-1691
5.
6.
7.
8.
9.
10.
Marron Servando E. Chernyshov Pavel V. Tomas-Aragones Lucia 《American journal of clinical dermatology》2019,20(4):527-538
American Journal of Clinical Dermatology - Acne patients may have significant quality-of-life (QoL) impairment, therefore assessment of health-related QoL (HRQoL) in acne patients is recommended by... 相似文献